SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Gastroenterology
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Erratum for Lau and Bleibel
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lau, D. T.-Y.
Right arrow Articles by Bleibel, W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Current status of antiviral therapy for hepatitis B

Daryl T.-Y. Lau

Harvard Medical School (HMS), Beth Israel Deaconess Medical Center, HMS Liver Center, Division of Gastroenterology, Department of Medicine, 110 Francis Street, Suite 4A, Boston, MA 02215, dlau{at}bidmc.harvard.edu

Wissam Bleibel

Liver Center, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Chronic hepatitis B (CHB) is a major public health problem affecting up to 400 million people globally. Complications of CHB including liver failure and hepatocellular carcinoma result in 1.2 million deaths per year, making CHB the 10th leading cause of mortality worldwide. The natural history of CHB is variable and complex. The past decade witnessed important developments for the therapy of hepatitis B and marked the new era of oral therapy. The ultimate goal of CHB therapy is to arrest the progression of liver injury and to prevent the development of liver failure and hepatocellular carcinoma. Currently, six agents are approved for the treatment of CHB. Each of these agents, given as monotherapy, has been shown to produce virological, biochemical, and histological benefits for both HBeAg positive and negative CHB. There are, however, limitations in spite of their efficacy. The significant side-effect profile of interferon, for example, limits its long-term use. The approved oral agents are tolerable with prolonged use but drug resistance could limit long-term monotherapy. To date, combination therapy with nucleoside analogue and pegylated interferon or two nucleos(t)ide analogues given for one year does not show superiority in durability of response compared to monotherapy. Ongoing research effort is critical to identify the ideal hepatitis B therapy that is safe, effective, and produces durable response with a finite course of therapy. It is equally important to conduct a well designed, prospective natural history study to identify predictors of disease progression. This will accurately guide treatment strategy for this important disease.

Key Words: Hepatitis B virus • pegylated interferon • nucleos(t)ide analogues • drug resistance

References

  • Alward, W.L., McMahon, B.J., Hall, D.B., Heyward, W.L., Francis, D.P. and Bender, T.R. (1985) The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 151(4): 604-609.[Medline] [Order article via Infotrieve]
  • Arora, G. and Keeffe, E.B. (2007) Chronic hepatitis B with advanced fibrosis or cirrhosis: impact of antiviral therapy. Rev Gastroenterol Disord 7(2): 63-73.[Medline] [Order article via Infotrieve]
  • Bondini, S., Kallman, J., Wheeler, A., Prakash, S., Gramlich, T., Jondle, D.M. et al. (2007) Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 27(5): 607-611.[CrossRef][Medline] [Order article via Infotrieve]
  • Chan, H.L., Hui, A.Y., Wong, M.L., Tse, A.M., Hung, L.C., Wong, V.W. et al. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53(10): 1494-1498.[Abstract/Free Full Text]
  • Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N. et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295(1): 65-73.[Abstract/Free Full Text]
  • Chu, C.M., Lin, D.Y. and Liaw, Y.F. (2007) Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond ) 31(5): 871-875.[Medline] [Order article via Infotrieve]
  • Colonno, R.J., Genovesi, E.V., Medina, I., Lamb, L., Durham, S.K., Huang, M.L. et al. (2001) Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 184(10): 1236-1245.[CrossRef][Medline] [Order article via Infotrieve]
  • Colonno, R.J., Rose, R., Baldick, C.J., Levine, S., Pokornowski, K., Yu, C.F. et al. (2006) Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44(6): 1656-1665.[CrossRef][Medline] [Order article via Infotrieve]
  • Cooksley, W.G., Piratvisuth, T., Lee, S.D., Mahachai, V., Chao, Y.C., Tanwandee, T. et al. (2003) Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10(4): 298-305.[CrossRef][Medline] [Order article via Infotrieve]
  • Del Poggio, P., Zaccanelli, M., Oggionni, M., Colombo, S., Jamoletti, C. and Puhalo, V. (2007) Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J Gastroenterol 13(30): 4096-4099.[Medline] [Order article via Infotrieve]
  • Doo, E. and Liang, T.J. (2001) Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 120(4): 1000-1008.[Medline] [Order article via Infotrieve]
  • Fan, Y.F., Lu, C.C., Chen, W.C., Yao, W.J., Wang, H.C., Chang, T.T. et al. (2001) Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33(1): 277-286.[CrossRef][Medline] [Order article via Infotrieve]
  • Fung, S.K., Chae, H.B., Fontana, R.J., Conjeevaram, H., Marrero, J., Oberhelman, K. et al. (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44(2): 283-290.[CrossRef][Medline] [Order article via Infotrieve]
  • Gish, R.G., Lau, D.T., Schmid, P. and Perrillo, R. (2007) A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 102(12): 2718-2723.[CrossRef][Medline] [Order article via Infotrieve]
  • Gish, R.G., Lok, A.S., Chang, T.T., de Man, R.A., Gadano, A., Sollano, J. et al. (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133(5): 1437-1444.[CrossRef][Medline] [Order article via Infotrieve]
  • Gordillo, R.M., Gutierrez, J. and Casal, M. (2005) Evaluation of the COBAS TaqMan 48 real-time PCR system for quantitation of hepatitis B virus DNA. J Clin Microbiol 43 (7): 3504-3507.[Abstract/Free Full Text]
  • Hadziyannis, S.J. and Vassilopoulos, D. (2001) Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 34(4 Pt 1): 617-624.[CrossRef][Medline] [Order article via Infotrieve]
  • Hadziyannis, S.J., Papatheodoridis, G.V. and Vassilopoulos, D. (2003) Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis 23(1): 81-88.[CrossRef][Medline] [Order article via Infotrieve]
  • Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M. et al. (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348(9): 800-807.[Abstract/Free Full Text]
  • Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M. et al. (2005) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352(26): 2673-2681.[Abstract/Free Full Text]
  • Hollinger, F.B. and Lau, D.T. (2006) Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin North Am 35(4): 895-931.[CrossRef][Medline] [Order article via Infotrieve]
  • Hoofnagle, J.H., Doo, E., Liang, T.J., Fleischer, R. and Lok, A.S. (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45(4): 1056-1075.[CrossRef][Medline] [Order article via Infotrieve]
  • Hoofnagle, J.H., Shafritz, D.A. and Popper, H. (1987) Chronic type B hepatitis and the `healthy` HBsAg carrier state. Hepatology 7(4): 758-763.[CrossRef][Medline] [Order article via Infotrieve]
  • Hu, K.Q., Currie, S.L., Shen, H., Cheung, R.C., Ho, S.B., Bini, E.J. et al. (2007) Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans. Dig Dis Sci 52(2): 570-578.[CrossRef][Medline] [Order article via Infotrieve]
  • Hunt, C.M., McGill, J.M., Allen, M.I. and Condreay, L.D. (2000) Clinical relevance of hepatitis B viral mutations. Hepatology 31(5): 1037-1044.[CrossRef][Medline] [Order article via Infotrieve]
  • Iloeje, U.H., Yang, H.I., Su, J., Jen, C.L., You, S.L. and Chen, C.J. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3): 678-686.[CrossRef][Medline] [Order article via Infotrieve]
  • Izzedine, H., Launay-Vacher, V. and Deray, G. (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45(5): 804-817.[CrossRef][Medline] [Order article via Infotrieve]
  • Janssen, H.L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U.S., Cakaloglu, Y. et al. (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365(9454): 123-129.[CrossRef][Medline] [Order article via Infotrieve]
  • Keeffe, E.B., Dieterich, D.T., Pawlotsky, J.M. and Benhamou, Y. (2008) Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol 6(3): 268-274.[CrossRef][Medline] [Order article via Infotrieve]
  • Keeffe, E.B., Zeuzem, S., Koff, R.S., Dieterich, D.T., Esteban-Mur, R., Gane, E.J. et al. (2007) Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5(8): 890-897.[CrossRef][Medline] [Order article via Infotrieve]
  • Kidd-Ljunggren, K., Miyakawa, Y. and Kidd, A.H. (2002) Genetic variability in hepatitis B viruses. J Gen Virol 83(Pt 6): 1267-1280.[Abstract/Free Full Text]
  • Kim, H.C., Nam, C.M., Jee, S.H., Han, K.H., Oh, D.K. and Suh, I. (2004) Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 328(7446): 983.[Abstract/Free Full Text]
  • Kim, J.H., Yu, S.K., Seo, Y.S., Yim, H.J., Yeon, J.E., Park, J.J. et al. (2007) Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy. J Gastroenterol Hepatol 22(8): 1220-1225.[CrossRef][Medline] [Order article via Infotrieve]
  • Lai, C.L., Gane, E., Liaw, Y.F., Hsu, C.W., Thongsawat, S., Wang, Y. et al. (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25): 2576-2588.[Abstract/Free Full Text]
  • Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z. et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354(10): 1011-1020.[Abstract/Free Full Text]
  • Lampertico, P., Vigano, M., Manenti, E., Iavarone, M., Sablon, E. and Colombo, M. (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133(5): 1445-1451.[CrossRef][Medline] [Order article via Infotrieve]
  • Laras, A., Koskinas, J., Dimou, E., Kostamena, A. and Hadziyannis, S.J. (2006) Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44(3): 694-702.[CrossRef][Medline] [Order article via Infotrieve]
  • Lau, D.T., Everhart, J., Kleiner, D.E., Park, Y., Vergalla, J., Schmid, P. et al. (1997) Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113(5): 1660-1667.[CrossRef][Medline] [Order article via Infotrieve]
  • Lau, D.T., Khokhar, M.F., Doo, E., Ghany, M.G., Herion, D., Park, Y. et al. (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32(4 Pt 1): 828-834.[CrossRef][Medline] [Order article via Infotrieve]
  • Lau, G.K., Piratvisuth, T., Luo, K.X., Marcellin, P., Thongsawat, S., Cooksley, G. et al. (2005)
  • Peginterferon Alfa- 2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352(26): 2682-2695.
  • Lau, G.K., Tsiang, M., Hou, J., Yuen, S., Carman, W.F., Zhang, L. et al. (2000) Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32(2): 394-399.[CrossRef][Medline] [Order article via Infotrieve]
  • Leandro, G., Mangia, A., Hui, J., Fabris, P., Rubbia-Brandt, L., Colloredo, G. et al. (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130(6): 1636-1642.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee, W.M. (1997) Hepatitis B virus infection. N Engl J Med 337(24): 1733-1745.[Free Full Text]
  • Leemans, W.F., Ter Borg, M.J. and de Man, R.A. (2007) Review article: Success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Aliment Pharmacol Ther 26 Suppl 2: 171-182.[Medline] [Order article via Infotrieve]
  • Leung, N.W., Lai, C.L., Chang, T.T., Guan, R., Lee, C.M., Ng, K.Y. et al. (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33(6): 1527-1532.[CrossRef][Medline] [Order article via Infotrieve]
  • Liaw, Y.F., Leung, N.W., Chang, T.T., Guan, R., Tai, D.I., Ng, K.Y. et al. (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119(1): 172-180.[CrossRef][Medline] [Order article via Infotrieve]
  • Liaw, Y.F., Sung, J.J., Chow, W.C., Farrell, G., Lee, C.Z., Yuen, H. et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15): 1521-1531.[Abstract/Free Full Text]
  • Lin, S.M., Sheen, I.S., Chien, R.N., Chu, C.M. and Liaw, Y.F. (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29(3): 971-975.[CrossRef][Medline] [Order article via Infotrieve]
  • Liu, C.J., Chen, P.J., Lai, M.Y., Kao, J.H. and Chen, D.S. (2001) Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34(3): 583-589.[CrossRef][Medline] [Order article via Infotrieve]
  • Livingston, S.E., Simonetti, J.P., McMahon, B.J., Bulkow, L.R., Hurlburt, K.J., Homan, C.E. et al. (2007) Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 195(1): 5-11.[CrossRef][Medline] [Order article via Infotrieve]
  • Locarnini, S. (2005) Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 25(Suppl 1): 9-19.[CrossRef][Medline] [Order article via Infotrieve]
  • Locarnini, S. and Mason, W.S. (2006) Cellular and virological mechanisms of HBV drug resistance. J Hepatol 44(2): 422-431.[CrossRef][Medline] [Order article via Infotrieve]
  • Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E.B., Liang, T.J., Mutimer, D. et al. (2004) Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9(5): 679-693.[Medline] [Order article via Infotrieve]
  • Lok, A.S. and McMahon, B.J. (2007) Chronic hepatitis B. Hepatology 45(2): 507-539.[CrossRef][Medline] [Order article via Infotrieve]
  • Lok, A.S., Chung, H.T., Liu, V.W. and Ma, O.C. (1993) Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105(6): 1833-1838.[Medline] [Order article via Infotrieve]
  • Lok, A.S., Heathcote, E.J. and Hoofnagle, J.H. (2001) Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 120(7): 1828-1853.[Medline] [Order article via Infotrieve]
  • Lole, K.S. and Arankalle, V.A. (2006) Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. J Virol Methods 135(1): 83-90.[CrossRef][Medline] [Order article via Infotrieve]
  • Magnius, L.O. and Norder, H. (1995) Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38(1-2): 24-34.[Medline] [Order article via Infotrieve]
  • Manesis, E.K. and Hadziyannis, S.J. (2001) Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121(1): 101-109.[CrossRef][Medline] [Order article via Infotrieve]
  • Marcellin, P., Lau, G.K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R. et al. (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351(12): 1206-1217.[Abstract/Free Full Text]
  • Margolis, H.S., Alter, M.J. and Hadler, S.C. (1991) Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11(2): 84-92.[Medline] [Order article via Infotrieve]
  • McMahon, B.J., Alward, W.L., Hall, D.B., Heyward, W.L., Bender, T.R., Francis, D.P. et al. (1985) Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 151(4): 599-603.[Medline] [Order article via Infotrieve]
  • McQuillan, G.M., Coleman, P.J., Kruszon-Moran, D., Moyer, L.A., Lambert, S.B. and Margolis, H.S. (1999) Prevalence of hepatitis B virus infection in the United States: the national health and nutrition examination surveys, 1976 through 1994. Am J Public Health 89(1): 14-18.[Abstract/Free Full Text]
  • Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C.M., Mohr, L. et al. (1996) Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334(22): 1422-1427.[Abstract/Free Full Text]
  • Okamoto, H., Tsuda, F., Akahane, Y., Sugai, Y., Yoshiba, M., Moriyama, K. et al. (1994) Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68(12): 8102-8110.[Abstract/Free Full Text]
  • Okamoto, H., Yotsumoto, S., Akahane, Y., Yamanaka, T., Miyazaki, Y., Sugai, Y. et al. (1990) Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64(3): 1298-1303.[Abstract/Free Full Text]
  • Ono-Nita, S.K., Kato, N., Shiratori, Y., Lan, K.H., Yoshida, H., Carrilho, F.J. et al. (1999) Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 103(12): 1635-1640.[Medline] [Order article via Infotrieve]
  • Papatheodoridis, G.V., Dimou, E., Dimakopoulos, K., Manolakopoulos, S., Rapti, I., Kitis, G. et al. (2005) Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42(1): 121-129.[CrossRef][Medline] [Order article via Infotrieve]
  • Patton, H.M., Patel, K., Behling, C., Bylund, D., Blatt, L.M., Vallee, M. et al. (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40(3): 484-490.[CrossRef][Medline] [Order article via Infotrieve]
  • Pawlotsky, J.M., Dusheiko, G., Hatzakis, A., Lau, D., Lau, G., Liang, T.J. et al. (2008) Virologic monitoring of hepatitis B virus therapy in clin trials and practice: recommendations for a standardized approach. Gastroenterology 134(2): 405-415.[CrossRef][Medline] [Order article via Infotrieve]
  • Perazella, M.A. (2003) Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 325(6): 349-362.[CrossRef][Medline] [Order article via Infotrieve]
  • Perrillo, R.P. (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120(4): 1009-1022.[Medline] [Order article via Infotrieve]
  • Sablon, E. and Shapiro, F. (2005) Advances in molecular diagnosis of HBV infection and drug resistance. Int J Med Sci 2(1): 8-16.[Medline] [Order article via Infotrieve]
  • Sablon, E., Shapiro, F. and Zoulim, F. (2003) Early detection of hepatitis B drug resistance: implications for patient management. Expert Rev Mol Diagn 3(5): 535-547.[CrossRef][Medline] [Order article via Infotrieve]
  • Sugauchi, F., Ohno, T., Orito, E., Sakugawa, H., Ichida, T., Komatsu, M. et al. (2003) Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 70(4): 537-544.[CrossRef][Medline] [Order article via Infotrieve]
  • Tacke, F., Manns, M.P. and Trautwein, C. (2004) Influence of mutations in the hepatitis B virus genome on virus replication and drug resistance- implications for novel antiviral strategies. Curr Med Chem 11(20): 2667-2677.[Medline] [Order article via Infotrieve]
  • Tan, J., Degertekin, B., Wong, S.N., Husain, M., Oberhelman, K. and Lok, A.S. (2008) Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 48(3): 391-398.[CrossRef][Medline] [Order article via Infotrieve]
  • Tenney, D.J., Levine, S.M., Rose, R.E., Walsh, A.W., Weinheimer, S.P., Discotto, L. et al. (2004) Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48(9): 3498-3507.[Abstract/Free Full Text]
  • Tsiang, M., Rooney, J.F., Toole, J.J. and Gibbs, C.S. (1999) Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29(6): 1863-1869.[CrossRef][Medline] [Order article via Infotrieve]
  • Villet, S., Pichoud, C., Billioud, G., Barraud, L., Durantel, S., Trepo, C. et al. (2008) Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48(5): 747-755.[Medline] [Order article via Infotrieve]
  • Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G. et al. (2004) Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126(7): 1750-1758.[CrossRef][Medline] [Order article via Infotrieve]
  • Yang, H., Qi, X., Sabogal, A., Miller, M., Xiong, S. and Delaney, W.E. 4th. (2005) Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10(5): 625-633.[Medline] [Order article via Infotrieve]
  • Yuen, M.F., Hui, C.K., Cheng, C.C., Wu, C.H., Lai, Y.P. and Lai, C.L. (2001) Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34(1): 139-145.[CrossRef][Medline] [Order article via Infotrieve]
  • Yuen, M.F., Tanaka, Y., Mizokami, M., Yuen, J.C., Wong, D.K., Yuan, H.J. et al. (2004) Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 25(9): 1593-1598.[Abstract/Free Full Text]
  • Zoulim, F. (2005) Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. J Antimicrob Chemother 55(5): 608-611.[Abstract/Free Full Text]
  • Zoulim, F. (2006) In vitro models for studying hepatitis B virus drug resistance. Semin Liver Dis 26(2): 171-180.[CrossRef][Medline] [Order article via Infotrieve]

Therapeutic Advances in Gastroenterology, Vol. 1, No. 1, 61-75 (2008)
DOI: 10.1177/1756283X08093944
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Erratum for Lau and Bleibel
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lau, D. T.-Y.
Right arrow Articles by Bleibel, W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement